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OBJECTIVE: There is increasing evidence that CIN has a sig-
niﬁcant impact on patient morbidity and mortality. Currently,
there is no systematic assessment of the cost of CIN and the
objective of this study is to estimate the in-hospital and one-year
direct health care cost related to CIN. METHODS: We per-
formed a thorough literature search using several databases
including MEDLINE® and the Cochrane Library to estimate the
incidence of CIN and understand the types of short-term and
long-term sequelae of CIN. We only retained studies that met
our inclusion criteria which included studies published after
1990 with a sample size of at least 100 patients that compared
outcomes of patient with and without CIN. Based on this review
we developed a decision analytic model to estimate the in-hos-
pital and one-year cost of CIN. One-way and two-way sensitiv-
ity analyses were performed. RESULTS: We identiﬁed 14 studies
that met our inclusion criteria. The overall rate of CIN was
10.0% (95% CI 6.6 to 13.4). Patients with CIN stayed longer
in the hospital (additional 3.65 days: 95%CI 1.6 to 5.7) and
were more likely to experience major adverse events both in-hos-
pital and during one-year follow-up. The average per patient
one-year cost due to CIN is $11,303 (range of $6132 to $13,847
in sensitivity analysis). About 4 million cardiac catheterizations
are performed in the US and Europe and over $4.5 billion
dollars, about $1000 per cardiac catheterization, could be spent
treating the sequelae of CIN. CONCLUSIONS: CIN results in
signiﬁcant health care costs and the expansion in the use of con-
trast media and increase in the prevalence of risk factors for CIN,
including diabetes and an aging population, will further increase
these costs in the future. Therefore, it is critical that cost-effec-
tive preventive strategies are adopted to reduce the clinical and
economic burden posed by CIN.
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OBJECTIVES: Clinical trials results expressed as relative risk
reduction may be misleading. It looks appropriate to assess the
poblational beneﬁt by modelling the beneﬁt demonstrated in the
trial. The objectives are: a) to estimate the number of events
avoided annually by Atorvastatin 80 mg (A80) vs. Pravastatin 
40 mg (P40) in ACS patients hospitalized in Spain, according to
PROVE-IT results, and b) to determine the incremental cost-
effectiveness ratio (ICER) of both alternatives. METHODS: a)
The poblational impact of treating all ACS Spanish patients with
A80 vs. P40 was estimated. Effectiveness data were obtained
from the PROVE-IT, the ﬁrst trial comparing two statins in ACS.
In this study, A80 was associated with a 3.9% absolute reduc-
tion in the primary endpoint, a composite of all cause mortality,
AMI, unstable angina, revascularization and stroke (22.4% A80
vs. 26.3% P40; p = 0.005). Estimated annual incidence of ACS
in Spain was 76,604; and b) A cost-effectiveness analysis model
based in a decision tree projected to 2 years was performed under
the National Health System (NHS) perspective. Only direct costs
were considered (€2005). Effectiveness was measured as primary
events avoided. RESULTS: If all ACS patients hospitalized in
Spain were treated with A80 for 2 years, in comparison with
what would happened when treated with P40, 2986 events
(including 792 deaths) would be avoided annually since the
second year of treatment. ICER of A80 vs. P40 was −€543/event
avoided, meaning that, according to the model, NHS would be
saving €543 for every event avoided by A80. These results were
robust to the sensitivity analysis, ﬂuctuating between a neutral
result and a beneﬁt for A80. CONCLUSIONS: In the reference
analysis, 2986 events would be avoided annually, including 792
deaths, by treating the entire Spanish ACS population with Ator-
vastatin 80 mg vs. Pravastatin 40 mg, with an average saving of
€1,621,400 for the NHS.
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OBJECTIVES: In the CURE trial, clopidogrel on top of aspirin
has been shown to reduce the number of cardiovascular events
(CV) deﬁned as myocardial death, myocardial infarction and
stroke, compared to aspirin alone by 20% in patients with unsta-
ble angina or non-ST-elevated myocardial infarction with an
acceptable 1% increase of major bleedings. Since acquisition
costs of clopidogrel is greater than aspirin, it is important to 
evaluate the cost-effectiveness of this strategy in Mexico.
METHODS: Costs were elicited from the IMSS mainly. (Social
Security System, 2005). A group of experts identiﬁed the
resource used by patients during a CV event. Study drug and
concomitant medications costs were calculated based on the
treatment duration reported in CURE, and costs of adverse
events were included. Effectiveness was measured as the total
number of events avoided. Sensitivity analyses were performed
on the mean costs of events and complications. RESULTS: The
mean cost per patient was US$10,614 for the clopidogrel arm
and $10,492 for aspirin. The incremental cost was higher due to
drug acquisition costs. Treatment with the clopidogrel strategy
reduced the number of events by 0.020 (0.1315 vs. 0.1114);
resulting in an incremental cost-effectiveness ratio (ICER) of
$6070/event avoided. In the sub-analysis of patients who under-
went PCI (PCI-CURE), the total cost reached $10,910 and
$10,721 for the clopidogrel and the aspirin strategy, respectively
while the number of events were 0.1165 with the clopidogrel
strategy and 0.1517 in the aspirin alone arm; resulting in an
ICER of $5369/event avoided. The sensitivity analysis high-
lighted that the maximum ICER in the CURE analysis was
$15,526, using the lowest cost/event reported and $9905/event
avoided in PCI-CURE sub-analysis. CONCLUSION: When
comparing the ICER with the acceptability threshold recom-
mended by WHO (i.e., ICER < 3xGDP per capita ($30,177),
clopidogrel on top of aspirin is highly cost-effective in
UA/NSTEMI patients within IMSS Mexico.
